Diane Mould

Founder & Chief Science Officer | Baysient
President | Projections Research Inc.
Pharmacokineticist

[Diane Mould @DRMOULD]

Adalimumab loss of response keeps clinicians up at night. Often, it's a clearance problem with a PK solution.

Read about it here: https://t.co/rirdqoTcnW

[Baysient LLC @baysient]

Up to 50% of adalimumab patients experience secondary loss of response. For many, it's pharmacokinetic: drug clearance varies, exposure drops, antibodies form.

iDose estimates individual clearance and personalizes dosing to reduce treatment failure.

https://t.co/zinm26oZM3

[Diane Mould @DRMOULD]

#ArthritisAwareness

[Baysient LLC @baysient]

iDose = decision support software for rheumatologists.

It calculates personalized biologic doses for RA patients based on their individual drug clearance, so doctors can optimize treatment instead of using standard dosing for everyone.

https://t.co/DwgCzcBJyb

[Diane Mould @DRMOULD]

If you're managing biologics for any of these conditions and want to see what precision dosing actually looks like in practice, schedule a demo with me to see how iDose works: https://t.co/JXSodMqG7I

[Baysient LLC @baysient]

Managing biologic therapy for inflammatory diseases? iDose GEN7.0 provides PK-informed dosing support for 17 indications.

Learn more: https://t.co/DwgCzcBJyb

[Baysient LLC @baysient]

May is #NationalNursesMonth

To the nurses managing infusions, coordinating care, catching complications, and advocating for patients:

Your clinical expertise and dedication make healthcare work.

Thank you.

[Diane Mould @DRMOULD]

Grateful to work alongside physicians who embrace data-driven approaches and prioritize individual patient needs over one-size-fits-all protocols. Your openness to precision medicine is changing outcomes.

Happy Doctors' Day!

[Diane Mould @DRMOULD]

After decades in PK modeling, this study reinforced something critical: we can predict treatment failure from the first dose, AND we can change those predictions with timely intervention. That's the power of precision medicine in practice.

[Baysient LLC @baysient]

IBD treatment paradigm shift:
❌ Reactive: Standard dose → wait for failure → adjust
✅ Proactive: Measure clearance → personalize immediately → prevent failure
https://t.co/Qwi86OSieg

[Diane Mould @DRMOULD]

The best treatments in the world only work when skilled nurses are there to implement them and advocate for patients. Thank you for being the backbone of GI care.

[Baysient LLC @baysient]

Celebrating GI Nurses & Associates Week! To all the GI nurses and associates managing infusions, monitoring treatments, and supporting patients: thank you. #GINursesWeek

[Diane Mould @DRMOULD]

Therapeutic drug monitoring isn't just for inflammatory diseases. Cancer patients receiving mAbs also face clearance variability and deserve the same personalized approach to optimize outcomes.

[Baysient LLC @baysient]

March is Colorectal Cancer Awareness Month. Therapeutic drug monitoring of monoclonal antibodies with TuMinimize helps oncology providers optimize treatment for each patient's individual characteristics. https://t.co/gOtT1G3ka6

[Diane Mould @DRMOULD]

Children with IBD deserve better than "try and see if it works." Pharmacokinetic monitoring gives us tools to optimize treatment from day one. Proud to share this research with the NICHD community.

[Baysient LLC @baysient]

How can individual PK monitoring help us track and slow disease progression in pediatric IBD? Baysient's @DRMOULD explores this in her NICHD Pediatric Clinical Pharmacology lecture. Now available to watch: https://t.co/zP9tu6wYnX

[Diane Mould @DRMOULD]

My lecture for the NICHD's Pediatric Clinical Pharmacology Series is now available. I cover disease activity vs. progression, biologic PK in pediatric patients, and how Bayesian adaptive dosing can inform more individualized treatment decisions in IBD.
https://t.co/tVyx1cobqX

[Diane Mould @DRMOULD]

Join me for the NICHD Pediatric Clinical Pharmacology Lecture Series - weekly sessions covering clinical pharmacology principles in pediatric populations.

Register now: https://t.co/i4bO1WwDMC

[Diane Mould @DRMOULD]

Major milestone for @Baysient: iDose GEN7.0 brings precision dosing to 16 inflammatory disease indications with predictive clinical capabilities.

[Baysient LLC @baysient]

NEWS: Baysient launches iDose GEN7.0, expanding precision dosing platform to 16 inflammatory disease indications across gastroenterology, rheumatology, dermatology & pulmonology.
Read the press release: https://t.co/isBPoGyPxp

[Diane Mould @DRMOULD]

When policy aligns with science, patients win. This decision protects access to the tools we need for smarter, more personalized dosing in IBD and beyond.

[Baysient LLC @baysient]

A federal court has ruled: TDM is governed by CLIA, not FDA. This keeps precision dosing tools like iDose available to providers without added regulatory hurdles.

https://t.co/79HRlK7wJj

[Diane Mould @DRMOULD]

Absolutely. Pediatric PK is fundamentally different. If we dose based on adult data, we miss the mark, and the child pays the price.

[Baysient LLC @baysient]

Kids aren’t just small adults. In pediatric IBD, faster clearance & subtherapeutic exposure demand precision, not scaled-down adult doses. iDose helps providers get ahead of treatment failure.

https://t.co/CHGaOpeyRi

[Diane Mould @DRMOULD]

This is exactly why we need regulatory flexibility and better pediatric trial design. These kids don’t have time for 7-year delays.

[Baysient LLC @baysient]

Pediatric IBD makes up 25% of new cases, yet most biologics aren’t approved for kids. With a 7+ year delay in approvals, kids rely on off-label use. We need smarter trials & tools like iDose to close the gap.

https://t.co/CHGaOpeyRi

[Diane Mould @DRMOULD]

I've said this for years — children aren’t just small adults. We owe them dosing strategies grounded in their biology, not in convenience.

[Baysient LLC @baysient]

Pediatric IBD ≠ adult IBD in smaller bodies. Kids clear drugs faster & respond differently.

It’s time to move from standard protocols to precision dosing with tools like iDose.

Let’s rethink pediatric IBD care.

📖 https://t.co/gZcLZw5ShG

[Diane Mould @DRMOULD]

This is exactly why we built iDose. Waiting for failure isn't good enough, especially in kids. We can model smarter, act earlier, and keep therapies working longer.

[Baysient LLC @baysient]

Reactive dosing often comes after response is lost. What if we could act sooner?

With iDose, pediatric GI docs can make preemptive, personalized adjustments, reducing antibody risk & treatment failure.

Smarter tools. Better timing.

https://t.co/gZcLZw5ShG

[Diane Mould @DRMOULD]

This gap has real consequences. We see the impact every day. Precision care shouldn't be age-dependent. We need to prioritize smarter pediatric trials now.

[Baysient LLC @baysient]

The avg delay between adult & pediatric approval for IBD biologics is 7+ years. In that time, kids are left waiting, failing therapies, & battling insurance.

We need smarter trials, better tools, & more flexibility. Kids can’t afford to wait.

[Diane Mould @DRMOULD]

The U.S. still treats IBD patients with a one-size-fits-all approach, especially with biologics. A new study in Chile is using @Baysient software to investigate how individualized dosing may improve outcomes. It's time we catch up.

📖 Study: https://t.co/DJnawpBXmS

[Diane Mould @DRMOULD]

@al_in_sweden Hi Alan
Drug clearance is PK its not PD. and as you would expect, patients whose clearance is fast, they tend to not respond well and fail earlier because their drug exposure (troughs) are low.

[Diane Mould @DRMOULD]

A new study highlights baseline clearance variability as a key factor in pediatric IBD treatment success. Therapeutic Drug Monitoring (TDM) can optimize Vedolizumab dosing to improve remission rates & reduce treatment failure.

Read more: https://t.co/z3UaFov61R.